NEW YORK, March 12, 2020 /PRNewswire/ — RemoteDesk by Verificient announces that in response to the recent coronavirus outbreak, RemoteDesk will be offering 10,000 (ten thousand) free licenses through the summer of 2020 to qualified businesses.
The coronavirus has taken many organizations, businesses, educational institutions, and governments by surprise and these groups are recommending that people work from home to help reduce the spread of the virus. However, the shift from working from the office to working from home presents many challenges: maintaining high productivity, preserving data security, and compliance.
Rahul Siddharth, COO, Verificient Technologies, Inc, “Remote workforce management needs to be the foundation of every organization’s emergency preparedness plan or disaster recovery plan. RemoteDesk can secure teleworkers’ home office workstations and ensure continued productivity during this sudden short term coronavirus pandemic. RemoteDesk can provide full transparency, mitigate the compliance and security risks of remote agents and help solve organizations’ critical needs in adopting a long term remote workforce.”
About RemoteDesk
RemoteDesk is the world’s most advanced AI-based remote workforce management solution for work-at-home compliance and security. RemoteDesk’s elegant and simple AI technology securely monitors teleworkers while providing clear transparency, accountability, work-at-home policy compliance, and risk management for outsourcing initiatives. RemoteDesk is powered by Verificient Technologies, Inc., which specializes in continuous identity verification through the use of its patented AI.
View original content to download multimedia:http://www.prnewswire.com/news-releases/remotedesk-offers-10-000-free-licenses-through-summer-2020-for-businesses-affected-by-coronavirus-301022150.html
SOURCE RemoteDesk
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…